Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

Teclistamab shows promising results in high-risk multiple myeloma patients, including those ineligible for trials due to ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

M ultiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

Multiple myeloma is a cancer of your bone marrow. Specifically, it affects your plasma cells, which are white blood cells that make antibodies to fight germs and prevent infection and disease ...

When you get a diagnosis of multiple myeloma, you may not even know what it is. Find out why this type of cancer is different from most others and what your treatment options look like.

Dr. Sundar Jagannath, a multiple myeloma expert at the Icahn School of Medicine at Mount Sinai, in New York, said he can now tell a 75-year-old, newly diagnosed patient they are unlikely to die of ...

Multiple myeloma is a rare blood cancer that is not hereditary. However, a family history of the disease may increase your risk of developing it.